## Vasilena Gocheva

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12057817/publications.pdf

Version: 2024-02-01

393982 794141 2,643 19 19 19 citations g-index h-index papers 19 19 19 4295 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes and Development, 2010, 24, 241-255.	2.7	594
2	Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes and Development, 2006, 20, 543-556.	2.7	475
3	Cysteine Cathepsins and the Cutting Edge of Cancer Invasion. Cell Cycle, 2007, 6, 60-64.	1.3	382
4	Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. Genes and Development, 2016, 30, 1020-1033.	2.7	122
5	Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development. Cancer Discovery, 2016, 6, 188-201.	7.7	122
6	Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E5625-E5634.	3.3	116
7	VEGF-A Induces Angiogenesis by Perturbing the Cathepsin-Cysteine Protease Inhibitor Balance in Venules, Causing Basement Membrane Degradation and Mother Vessel Formation. Cancer Research, 2009, 69, 4537-4544.	0.4	110
8	Distinct functions of macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix. Genes and Development, 2014, 28, 2134-2150.	2.7	92
9	Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. Genes and Development, 2015, 29, 1850-1862.	2.7	87
10	Proteomic Identification of Cysteine Cathepsin Substrates Shed from the Surface of Cancer Cells. Molecular and Cellular Proteomics, 2015, 14, 2213-2228.	2.5	82
11	Deletion of cathepsin H perturbs angiogenic switching, vascularization and growth of tumors in a mouse model of pancreatic islet cell cancer. Biological Chemistry, 2010, 391, 937-45.	1.2	68
12	Design, Synthesis, and Evaluation of In Vivo Potency and Selectivity of Epoxysuccinyl-Based Inhibitors of Papain-Family Cysteine Proteases. Chemistry and Biology, 2007, 14, 499-511.	6.2	67
13	Cathepsin-mediated Necrosis Controls the Adaptive Immune Response by Th2 (T helper type 2)-associated Adjuvants. Journal of Biological Chemistry, 2013, 288, 7481-7491.	1.6	66
14	TAILS N-Terminomics and Proteomics Show Protein Degradation Dominates over Proteolytic Processing by Cathepsins in Pancreatic Tumors. Cell Reports, 2016, 16, 1762-1773.	2.9	66
15	Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. Biochimie, 2010, 92, 1618-1624.	1.3	53
16	Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer. Genes and Development, 2016, 30, 220-232.	2.7	50
17	Legumain is activated in macrophages during pancreatitis. American Journal of Physiology - Renal Physiology, 2016, 311, G548-G560.	1.6	35
18	Inducible de novo expression of neoantigens in tumor cells and mice. Nature Biotechnology, 2021, 39, 64-73.	9.4	32

#	Article	lF	CITATIONS
19	Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma. Cancer & Metabolism, 2018, 6, 6.	2.4	24